Charles Y. Lin - 16 Feb 2024 Form 3 Insider Report for Kronos Bio, Inc. (KRON)

Role
SR VP, RESEARCH & DEVELOPMENT
Signature
/s/ Allison Frisbee, Attorney-in-Fact
Issuer symbol
KRON
Transactions as of
16 Feb 2024
Net transactions value
$0
Form type
3
Filing time
23 Feb 2024, 20:06:34 UTC
Next filing
23 Feb 2024
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
holding KRON Common Stock 246,639 16 Feb 2024 Direct

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
holding KRON Stock Option (Right to Buy) 16 Feb 2024 Common Stock 152,975 $2.53 Direct F1
holding KRON Stock Option (Right to Buy) 16 Feb 2024 Common Stock 37,030 $28.82 Direct F2
holding KRON Stock Option (Right to Buy) 16 Feb 2024 Common Stock 57,500 $7.08 Direct F3
holding KRON Stock Option (Right to Buy) 16 Feb 2024 Common Stock 81,920 $2.09 Direct F4
holding KRON Stock Option (Right to Buy) 16 Feb 2024 Common Stock 145,795 $1.08 Direct F5
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 25% of the shares vested on December 20, 2020, and the remaining shares shall vest in 36 equal monthly installments.
F2 The shares vest in 48 equal monthly installments beginning on February 16, 2021.
F3 The shares vest in 48 equal monthly installments beginning on February 15, 2022.
F4 The shares vest in 48 equal monthly installments beginning on February 15, 2023.
F5 The shares vest in 48 equal monthly installments beginning on February 15, 2024.